JENNY C-N CHANG

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients
    J Chang
    Breast Center, Baylor College of Medicine, Houston Texas 77030, and Departments of Medical Oncology and Pathology, National University of Singapore, Singapore 0511
    Clin Cancer Res 7:1739-42. 2001
  2. ncbi request reprint Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer
    Jenny C Chang
    Breast Center and the Departments of Medicine, Pathology, and Molecular and Cellular Biology, Baylor College of Medicine, and The Methodist Hospital, Houston, TX 77030, USA
    Lancet 362:362-9. 2003
  3. pmc Genomic approaches in the management and treatment of breast cancer
    J C Chang
    Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Br J Cancer 92:618-24. 2005
  4. ncbi request reprint Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients
    Jenny C Chang
    Breast Center, Department of Medicine, Baylor College of Medicine, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
    J Clin Oncol 23:1169-77. 2005
  5. pmc The promise of microarrays in the management and treatment of breast cancer
    Jenny C Chang
    Breast Center, Baylor College of Medicine, Houston, Texas, USA
    Breast Cancer Res 7:100-4. 2005
  6. ncbi request reprint HER2 inhibition: from discovery to clinical practice
    Jenny C Chang
    Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 13:1-3. 2007
  7. ncbi request reprint The structure of denatured bovine pancreatic trypsin inhibitor (BPTI)
    J Chang
    Research Center for Protein Chemistry, Institute of Molecular Medicine, The University of Texas, 2121 W Holcombe Blvd, Houston, TX, USA
    FEBS Lett 473:183-7. 2000
  8. ncbi request reprint Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma
    J Chang
    Department of Biochemistry, Medicine and Computing, The Royal Marden Hospital, Sutton, Surrey, United Kingdom
    Cancer 89:2145-52. 2000
  9. ncbi request reprint Clinical management of women with genomic BRCA1 and BRCA2 mutations
    J Chang
    Department of Medicine, Baylor Methodist Breast Care Center, Baylor College of Medicine, Houston, TX 77030, USA
    Breast Cancer Res Treat 69:101-13. 2001

Detail Information

Publications9

  1. ncbi request reprint Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients
    J Chang
    Breast Center, Baylor College of Medicine, Houston Texas 77030, and Departments of Medical Oncology and Pathology, National University of Singapore, Singapore 0511
    Clin Cancer Res 7:1739-42. 2001
    ..The aim of this study is to determine whether morphological features of breast cancers in premenopausal patients (age < 45 years) could determine additional women who may benefit from BRCA1 screening...
  2. ncbi request reprint Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer
    Jenny C Chang
    Breast Center and the Departments of Medicine, Pathology, and Molecular and Cellular Biology, Baylor College of Medicine, and The Methodist Hospital, Houston, TX 77030, USA
    Lancet 362:362-9. 2003
    ..Patients often have de novo resistance or incomplete response to docetaxel, one of the most active agents in this disease. We postulated that gene expression profiles of the primary breast cancer can predict the response to docetaxel...
  3. pmc Genomic approaches in the management and treatment of breast cancer
    J C Chang
    Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Br J Cancer 92:618-24. 2005
    ..The most recent application of microarray genomic technologies to studying breast cancer will be the focus of this review...
  4. ncbi request reprint Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients
    Jenny C Chang
    Breast Center, Department of Medicine, Baylor College of Medicine, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
    J Clin Oncol 23:1169-77. 2005
    ..Chemotherapy for operable breast cancer decreases the risk of death. Docetaxel is one of the most active agents in breast cancer, but resistance or incomplete response is frequent...
  5. pmc The promise of microarrays in the management and treatment of breast cancer
    Jenny C Chang
    Breast Center, Baylor College of Medicine, Houston, Texas, USA
    Breast Cancer Res 7:100-4. 2005
    ..The most recent application of microarray genomic technologies to studying breast cancer is the focus of this review...
  6. ncbi request reprint HER2 inhibition: from discovery to clinical practice
    Jenny C Chang
    Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 13:1-3. 2007
  7. ncbi request reprint The structure of denatured bovine pancreatic trypsin inhibitor (BPTI)
    J Chang
    Research Center for Protein Chemistry, Institute of Molecular Medicine, The University of Texas, 2121 W Holcombe Blvd, Houston, TX, USA
    FEBS Lett 473:183-7. 2000
    ..The extreme conformational stability of BPTI has important implications in its distinctive folding pathway...
  8. ncbi request reprint Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma
    J Chang
    Department of Biochemistry, Medicine and Computing, The Royal Marden Hospital, Sutton, Surrey, United Kingdom
    Cancer 89:2145-52. 2000
    ..The objective of this clinical study was to examine in vivo changes in apoptotic index (AI), Bcl-2 expression, proliferation (Ki-67 and S-phase fraction [SPF]), and ploidy as potential indicators of chemoresponsiveness...
  9. ncbi request reprint Clinical management of women with genomic BRCA1 and BRCA2 mutations
    J Chang
    Department of Medicine, Baylor Methodist Breast Care Center, Baylor College of Medicine, Houston, TX 77030, USA
    Breast Cancer Res Treat 69:101-13. 2001
    ..The purpose of this report is to review the current state of knowledge of BRCA1 and BRCA2, the biology of associated tumors, and possible risk reduction strategies in women with these deleterious mutations...

Research Grants9

  1. Breast cancer response markers to a dual HER1/2 blocker
    Jenny Chang; Fiscal Year: 2009
    ....
  2. MECHANISM OF ACTION OF HERCEPTIN R IN BREAST CANCER
    Jenny Chang; Fiscal Year: 2002
    ....
  3. Breast cancer response markers to a dual HER1/2 blocker
    Jenny Chang; Fiscal Year: 2005
    ....
  4. Breast cancer response markers to a dual HER1/2 blocker
    Jenny Chang; Fiscal Year: 2006
    ....
  5. Breast cancer response markers to a dual HER1/2 blocker
    Jenny Chang; Fiscal Year: 2007
    ....
  6. Targeting Notch, PI3K-AKT and other novel pathways in breast cancer stem cells
    Jenny Chang; Fiscal Year: 2009
    ..Correlative studies using human cancer biopsies from these trials will be conducted, e.g. a decrease in stem cell markers and tumorigenic potential, as well as downstream effects of inhibition of the relevant pathways. ..